HCM Hutchison China Meditech Ltd Sponsored ADR

HUTCHMED to Announce 2023 Final Results

HUTCHMED to Announce 2023 Final Results

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 01, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year ended December 31, 2023 on Wednesday, February 28, 2024 at 6:30 am Eastern Standard Time (EST) / 11:30 am Greenwich Mean Time (GMT) / 7:30 pm Hong Kong Time (HKT).

Analysts and investors are invited to join a conference call and audio webcast presentation with Q&A, conducted by HUTCHMED management.

The English conference call and audio webcast will take place at 7:30 am EST / 12:30 pm GMT / 8:30 pm HKT on Wednesday, February 28, 2024. In addition to the usual English webcast, there will also be a Chinese (Putonghua) webcast at 7:30 pm EST / 12:30 am GMT / 8:30 am HKT on Thursday, February 29, 2024. Both webcasts will be available live via the company website at . The presentation will be available for downloading before the conference call begins. Details of the conference call dial-in will be provided in the financial results announcement and on the company website. A replay will also be available on the website shortly after the event.

About HUTCHMED

HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has approximately 5,000 personnel across all its companies, at the center of which is a team of about 1,800 in oncology/immunology. Since inception it has focused on bringing cancer drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also marketed in the U.S. For more information, please visit: or follow us on .

CONTACTS

Investor Enquiries+852 2121 8200 /
  
Media Enquiries 
Ben Atwell / Alex Shaw, FTI Consulting+44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile) /

Zhou Yi, Brunswick+852 9783 6894 (Mobile) /
  
Nominated Advisor 
Atholl Tweedie / Freddy Crossley / Daphne Zhang, Panmure Gordon+44 20 7886 2500



EN
01/02/2024

Underlying

Reports on Hutchison China Meditech Ltd Sponsored ADR

Carol Dou Xiao Qin ... (+2)
  • Carol Dou Xiao Qin
  • Sunny Chen

HUTCHMED (China) (13 HK): 1H25: Divestment of non-core asset boosts ea...

1H25 revenue missed forecasts, but its robust earnings of US$455.6m beat market estimates. It targets lower oncology revenue of US$270m-350m on delays in milestone income and setbacks in Sovleplenib’s review progress, and expects domestic sales to recover from 2H25. Seeing smooth R&D progress and market approvals in major oncology products, HUTCHMED will likely see a new wave of market approvals to fuel growth in the years ahead. Maintain BUY with a lower target price of HK$32.50.

Bella Lu Yifei ... (+9)
  • Bella Lu Yifei
  • Carol Dou Xiao Qin
  • Claire Wang Kelai
  • Damon Shen
  • Greater China Research Team
  • Jieqi Liu
  • Ken Lee
  • Sunny Chen
  • Tham Mun Hon

Greater China Daily: Friday, August 8, 2025

Economics Trade July exports grew 7.2% yoy (+1.4ppts), with continued strength in exports to the ASEAN and EU markets. Import growth improved to 4.1% yoy (+3ppt), likely due to a lower base, and support from strong imports of integrated circuits and agricultural products. However, imports of some key commodities saw sharp declines. The Sino-US agreement on another 90-day trade truce may continue to support near-term trade activities. Sector Automobile China’s PV insurance registrations reboun...

Franc Gregori ... (+3)
  • Franc Gregori
  • Lala Gregorek
  • Philippa Gardner

Trinity Delta Lighthouse: HUTCHMED

Trinity Delta view: The China sales decline, plus lowering of revenue guidance are undoubtedly disappointing. However, China growth is already improving and management is confident this will continue during H225, driven by new indications. In particular, the recent Orpathys/Tagrisso approval based on SACHI data represent a much larger indication; importantly, data from the global SAFFRON trial are expected H126. Furthermore, as the sizeable ATTC opportunities become clearer, these could offer si...

 PRESS RELEASE

HUTCHMED Reports 2025 Interim Results

HUTCHMED Reports 2025 Interim Results — Indications expansion driving growth and ATTC platform enriching pipeline — — $455 million in net income attributable to HUTCHMED driven by non-core partial disposal — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“”, the “Company” or “we”) (Nasdaq/AIM:​HCM; HKEX:​13) today reports its financial results for the six months ended June 30, 2025 and provides updates on key clinical and commercial developments. HUTCHMED to host results webcasts today at 8:00 a.m. EDT / 1:00 p.m. BST / 8:00 p...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch